CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study

Abstract

Background To our knowledge, no controlled studies of the effects of long-term growth hormone replacement on fracture risk in adult patients with growth hormone deficiency exist. We assessed the effect of growth hormone treatment on fracture risk in patients with growth hormone deficiency from the international Hypopituitary Control and Complications Study (HypoCCS) surveillance database. Methods In this prospective cohort study, patients with growth hormone deficiency were analysed from the HypoCCS database of adults with hypopituitarism from the USA, Canada, Japan, and 14 European countries. Patients were eligible if they were aged 18 years or older and had an established diagnosis of growth hormone deficiency, either alone or with multiple pituitary hormone deficiencies, as identified by clinical history and biochemical testing. Patients were assessed over a mean follow-up period of 4·6 years (SD 3·8). The effect of growth hormone treatment on fracture risk was assessed by Cox proportional hazard modelling with adjustment for several confounders. Findings Between Jan 3, 1996, and Dec 15, 2012, we enrolled 10,673 patients to this study. Of the enrolled patients, 1032 patients were excluded from assessment because of incomplete data, leaving 9641 in the analysis cohort. Of these patients, 8374 of received growth hormone and 1267 did not. Annual fracture incidence rate was lower in patients who received growth hormone than in those who did not (fracture incidence rate 1·19% v…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(15)00098-4

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 64

Metadata

Authors
Mo, D., Fleseriu, M., Qi, R., Jia, N., Child, C. J., Bouillon, R., & Hardin, D. S.
Affiliations
  • Eli Lilly (United States) (US)
  • Oregon Health & Science University (US)
  • Eli Lilly (United Kingdom) (GB)
  • KU Leuven (BE)
Corresponding author
Mo, Daojun
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2015-05
Volume
3
Issue
5
Pages
331-338
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2114943750
Cited by
64
References
41
Citations by year
2026: 2 · 2025: 7 · 2024: 9 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 1 · 2018: 11 · 2017: 4 · 2016: 7 · 2015: 4
FWCI
7.53
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
growth hormone replacement therapy, growth hormone deficiency, fracture risk, hypopituitarism, osteoporosis, bone health, multiple pituitary hormone deficiency
MeSH terms
Adult, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Incidence, Human Growth Hormone, Hormone Replacement Therapy, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00098-4
The paper
Mo, D., Fleseriu, M., Qi, R., Jia, N., Child, C. J., Bouillon, R., & Hardin, D. S. (2015). Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00098-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.